Alphabet is seeking regulatory approval to release millions of specially treated, non-biting mosquitoes in California and Florida [1, 2].

The initiative represents a high-tech approach to public health by attempting to suppress insect populations that carry dangerous pathogens. If successful, the project could significantly reduce the transmission of mosquito-borne illnesses in high-risk regions of the U.S.

The company plans to use mosquitoes infected with Wolbachia bacteria [3]. This specific biological intervention is designed to prevent the insects from spreading diseases such as dengue and malaria [1, 2]. By introducing these treated mosquitoes into the wild, Alphabet aims to crash the population of disease-carrying species.

Scale of the project varies by region. Alphabet has proposed releasing 32 million mosquitoes specifically for the California project [4]. Across the broader U.S. effort, the company aims to release up to 64 million bacteria-laden mosquitoes [3].

These filings occurred during a 2024 regulatory period [1]. The project focuses on two primary states, California and Florida, where the risk of tropical disease transmission is increasing [1, 2].

The use of Wolbachia is a known method in biological control. The bacteria interfere with the mosquito's ability to transmit viruses to humans and can also limit the reproductive success of the wild population. This method provides an alternative to traditional chemical spraying, which can impact other pollinators and the environment.

“Alphabet aims to release up to 64 million bacteria-laden mosquitoes in the US.”

This move signals a shift toward biological engineering as a primary tool for urban disease management. By leveraging Wolbachia bacteria, Alphabet is attempting to create a self-sustaining biological barrier against outbreaks, moving away from reactive chemical treatments toward a preventative, systemic ecological intervention.